OSE Immuno Shares Drop 8% and Fall Below €4
The Nantes-based biotech's stock undergoes a sharp correction during the session, contrary to a significantly bullish Parisian market. This movement comes a few days after the release of the 2025 financial statements and several funding announcements, in a context where healthcare stocks remain particularly sensitive to flows and clinical timelines.
Significant Decline Amidst Market Contrasts
OSE Immuno shares lose 8.54% to €4.00, while the CAC 40 gains 1.78% and the SBF 120 increases by 1.74%. The stock is among the steepest declines in the CAC All Shares. This session contrasts with the dynamics of the last seven days, during which the stock still posted a gain of 8.2%, indicating high volatility typical of small-cap biotechs.
Over three months, the performance remains barely positive (+1.6%), while the decline reaches 24.3% over one year. The market context does not provide a direct explanation for this downturn: the ECB has raised its rates by 25 basis points and Brent crude has retreated to $89, but these factors have little impact on a biotech without recurring revenue. The movement occurs after recent financing announcements.
Break Below the 20-Day Moving Average and Secured Cash Until End of 2026
Today's decline brings the price below the 20-day moving average, located at €4.43 (a gap of -9.6%), and confirms the distancing from the 200-day moving average at €4.86. However, the stock still has a cushion above the 50-day moving average at €3.92, which will be the next defense zone, with technical support identified at €3.46. The RSI at 55 remains neutral despite today's drop, reflecting the magnitude of the previous rally. Fundamentally, the 2025 financial statements published on June 4 reported a net loss of €37.7 million and a revenue drop of 96% to €2.6 million, although the company still estimates its cash sufficient until the end of December 2026.
This visibility was reinforced by the IRIS Capital agreement on May 28, which could raise up to €19.3 million through warrants. During the results announcement on May 22, 2026, the company highlighted the progress of the Tedopi-pembrolizumab combination in progression-free survival, the main revaluation lever in the medium term. Crossing the 50-day moving average at €3.92 remains the technical threshold to watch in the coming sessions.
